急性重症溃疡性结肠炎的药物治疗:系统评价与Meta分析
该系统评价与Meta分析检索至2024年11月14日,纳入44项研究(18项随机对照试验、26项队列研究),评估22种比较。低确定性证据提示英夫利西单抗在降低出院、3个月和12个月结肠切除风险方面优于环孢素A,但感染风险更高。托法替尼联合静脉糖皮质激素在第7天临床应答诱导上优于单用静脉糖皮质激素。
要点
- 英夫利西单抗较环孢素A降低出院、3个月和12个月结肠切除风险,但感染风险更高。
- 英夫利西单抗加速与标准给药方案在出院或3个月结肠切除率上无显著差异。
- 托法替尼联合静脉糖皮质激素第7天临床应答优于单用静脉糖皮质激素。
核心结论
- 英夫利西单抗治疗急性重症溃疡性结肠炎可能比环孢素A更有效。
- Janus激酶抑制剂是特定个体的有前景治疗选择。
- 未来研究应探索其他先进疗法的疗效。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE和CENTRAL至2024年11月14日。
- 纳入评估住院成人急性重症溃疡性结肠炎药物治疗的随机对照试验(安慰剂或阳性对照)和比较性队列研究。
- 共纳入44项研究(18项随机对照试验和26项队列研究),评估22种不同比较。
- 主要结局为出院时、3个月和12个月结肠切除率;安全性结局包括不良事件、严重不良事件和感染。
- 计算合并风险比(RR)和95%置信区间(CI)。
主要发现
- 低确定性证据提示英夫利西单抗在降低出院时结肠切除风险上显著优于环孢素A(RR 0.56;95%CI 0.38-0.81;I²=30%)。
- 英夫利西单抗在降低3个月结肠切除风险上显著优于环孢素A(RR 0.67;95%CI 0.48-0.92;I²=36%)。
- 英夫利西单抗在降低12个月结肠切除风险上显著优于环孢素A(RR 0.56;95%CI 0.42-0.75;I²=46%)。
- 英夫利西单抗组患者较环孢素A组患者更可能发生感染(RR 2.38;95%CI 1.27-4.47;I²=15%)。
- 英夫利西单抗加速给药方案与标准给药方案在出院时或3个月结肠切除率上无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Acute severe ulcerative colitis (ASUC) is a medical emergency associated with high morbidity and mortality. We aimed to assess the efficacy and safety of medical treatments for ASUC. METHODS: MEDLINE, EMBASE, and CENTRAL were searched to November 14, 2024 for randomized controlled trials (placebo or active comparator), and comparative cohort studies that evaluated medical therapies for hospitalized adults with ASUC. Primary outcomes were colectomy rate at discharge and at 3 and 12 months. Safety outcomes included adverse events, serious adverse events, and infections. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated. RESULTS: Forty-four studies (18 randomized controlled trials, and 26 cohort studies) assessing 22 different comparisons were included. Low certainty evidence suggests that infliximab (IFX) was significantly superior to cyclosporine A for reducing the risk of colectomy at discharge (RR, 0.56; 95% CI, 0.38-0.81; I2 = 30%), 3 months (RR, 0.67; 95% CI, 0.48-0.92; I2 = 36%), and 12 months (RR, 0.56; 95% CI, 0.42-0.75; I2 = 46%). IFX patients were significantly more likely than cyclosporine A patients to develop an infection (RR, 2.38; 95% CI, 1.27-4.47; I2 = 15%). There was no significant difference between accelerated and standard dosing regimens of IFX for colectomy at discharge or at 3 months. Tofacitinib in combination with intravenous corticosteroids was significantly superior to intravenous corticosteroids alone for induction of clinical response at Day 7; however, there was no difference in colectomy rate or infections at 3 months. CONCLUSIONS: IFX may be more efficacious than cyclosporine A for the treatment of ASUC. Janus kinase inhibitors are promising treatment options in select individuals. Future studies should explore the efficacy of other advanced therapies.
引用
- Vuyyuru SK, Shaban N, Yuan Y, et al. Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysis. Clin Gastroenterol Hepatol. 2025. PMID: 40339949. doi:10.1016/j.cgh.2025.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。